ABOUT
LIVTENCITY (maribavir) is indicated for the treatment of adults with post-transplant cytomegalovirus (CMV)
infection and disease resistant, refractory or intolerant to one or more prior therapies.1
CMV, cytomegalovirus; PBS, Pharmaceutical Benefits Scheme
Understanding the clinical data
PBS Information: This product is listed on the PBS. Authority required. Refer to PBS Schedule for full authority information.
Click here to review the full Product Information before prescribing.
| ▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems |
REFERENCES
- LIVTENCITY® Approved Product Information
- Avery RK, et al. Clin Infect Dis. 2022;75(4):690-701
- Australian Government Department of Health and Aged Care. Pharmaceuticals Benefits Scheme. www.pbs.gov.au. Accessed July 2025.
REFERENCES
- LIVTENCITY® Approved Product Information
- Avery RK, et al. Clin Infect Dis. 2022;75(4):690-701
- Australian Government Department of Health and Aged Care. Pharmaceuticals Benefits Scheme. www.pbs.gov.au. Accessed July 2025.